툴젠

199800KOSDAQ자연과학 및 공학 연구개발업

60.3 / 100

Reference Date: 2026-04-13

Financial Score16.5 / 40

News Sentiment16.8 / 25

Momentum17.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PBR raises overvaluation concerns. Surged 29.5% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Toolgen specializes in gene-editing R&D, patent monetization, and the development of therapeutics and functional seeds using CRISPR/Cas9 and other technologies. As the world's only company to develop three types of gene-editing tools (ZFN, TALEN, CRISPR/Cas9), it leads in therapeutic drug development (e.g., TGT-001, TG-wAMD) and functional crop seed innovation (e.g., high-oleic soybeans, disease-resistant potatoes).

Number of Employees

66people

Average Salary

72.3M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 120.074.0Point

PBR

10.08Industry Average 3.820.0Point

2.6x industry avg (risky)

ROE

-64.34Industry Average -32.113.5Point

2.0x industry avg (excellent)

Debt Ratio

2.89Industry Average 7.526.5Point

Half of industry avg (excellent)

Trend 2023~20252.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲13.7% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼17.2% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -44.8% (improving, 3yr)

Detailed News Sentiment

7 totalPositive 2Neutral 2Negative 0Average Sentiment Score 80

Positive
유전자가위 치료제 글로벌 특허전 분기점…툴젠 주가 왜 올랐나
미국 특허심판원이 유전자가위 기술 특허 분쟁에서 브로드연구소의 손을 들어주면서 지연됐던 툴젠의 저촉심사 2단계 재개 가능성이 커져 주가가 급등했습니다.
Positive
유종상 툴젠 대표 “크리스퍼 카스9 특허전, 하반기 본게임…3자합의.....
유종상 툴젠 대표는 글로벌 크리스퍼 유전자 가위 원천특허 분쟁의 본게임이 올 하반기 초부터 시작될 것이며, 경쟁사 간 합의 가능성도 높아질 것이라고 밝혔습니다.
Neutral
프로젠, 이병화 CFO 영입…"코스닥 이전상장 본격 준비"
프로젠이 코스닥 이전상장을 위해 이병화 CFO를 영입했으며, 이병화 사장은 과거 툴젠의 대표이사를 역임한 바 있습니다.

Detailed Momentum

52-week position6.0Point

52w upper range (72%)

Current 62,600Won52-week high 76,20052-week low 27,000

1-month return6.0Point

1m +29.47% (strong rise)

Volume trend5.0Point

Volume increasing

Detailed Disclosure

7 totalPositive 0Neutral 7Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-07
Neutral주식등의대량보유상황보고서(일반)2026-04-07
Neutral[기재정정]주식등의대량보유상황보고서(일반)2026-04-07
Neutral정기주주총회결과2026-03-27
Neutral사업보고서 (2025.12)2026-03-19